The use of SGLT2 inhibitors in the treatment of cognitive disorders

Authors

  • Marta Lato Szpital Specjalistyczny im.J.Dietla w Krakowie, ul.Skarbowa 1, 31-121 Kraków https://orcid.org/0000-0003-4121-3400
  • Konrad Iberszer Samodzielny Publiczny Szpital Kliniczny nr 4, ul. Jaczewskiego 8, 20-954 Lublin https://orcid.org/0000-0002-4290-9883
  • Maria Litwiniuk WOJEWÓDZKI SZPITAL SPECJALISTYCZNY im. Stefana Kardynała Wyszyńskiego Samodzielny Publiczny Zakład Opieki Zdrowotnej w Lublinie,  Al. Kraśnicka 100, 20-718 Lublin https://orcid.org/0009-0004-5396-7482
  • Marcin Zaniuk Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA w Lublinie, ul. Grenadierów 3, 20-331 Lublin https://orcid.org/0000-0003-4643-0594
  • Kamil Hurkała Samodzielny Publiczny Szpital Wojewódzki im. Papieża Jana Pawła II w Zamościu, ul. Aleje Jana Pawła II 10, 22-400 Zamość https://orcid.org/0009-0007-5961-9894
  • Dominika Antonik 5 Wojskowy Szpital Kliniczny z Polikliniką w Krakowie, ul. Wrocławska ⅓, 30-901 Kraków https://orcid.org/0009-0004-7575-8016
  • Barbara Denys WOJEWÓDZKI SZPITAL SPECJALISTYCZNY im. Stefana Kardynała Wyszyńskiego Samodzielny Publiczny Zakład Opieki Zdrowotnej w Lublinie,  Al. Kraśnicka 100, 20-718 Lublin https://orcid.org/0009-0003-1951-1142
  • Karolina Góra Samodzielny Publiczny Szpital Kliniczny nr 4, ul. Jaczewskiego 8, 20-954 Lublin https://orcid.org/0000-0002-5377-3010
  • Wojciech Zdziennicki Uniwersytecki Szpital Kliniczny w Poznaniu - ul. Przybyszewskiego 49, 60-355 Poznań https://orcid.org/0009-0005-1254-9740
  • Patryk Zimnicki Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA w Lublinie, ul. Grenadierów 3, 20-331 Lublin https://orcid.org/0000-0002-5808-8661

DOI:

https://doi.org/10.12775/JEHS.2023.25.01.003

Keywords

SGLT2 inhibitors, type 2 diabetes mellitus, neuroprotection, oxidative stress, mTOR, Alzheimer disease, Parkinson disease

Abstract

Background:Dementia is a progressive and irreversible disease entity that affects memory, verbal fluency, thinking and the performance of daily activities.The most common type of dementia is alzheimer's disease(AD).Currently, there are no specific therapies with established efficacy against cognitive decline or AD.
Objective:The aim of this study is to summarize the current knowledge about the effectiveness of SGLT2 inhibitors(SGLT2i) in the treatment of cognitive disorders.
Method and material:The article was created based on the PubMed database and the Polish Journal of Endocrinology.Articles were searched in English using the following keywords: SGLT2ihibitors;dementia;Alzheimer type 3 diabetes mellitus.
State of knowledge:Patients with type 2 diabetes (TD2) are 1.5-2 times more likely to develop dementia than the general population.Dementia among diabetic patients is characterized by an earlier age of onset, slightly worse overall cognitive status and a higher prevalence of cognitive impairment in male patients.Diabetes and pre-diabetes shorten the time from the onset of mild cognitive impairment (MCI) to the development of full-blown dementia.
Conclusions:The use of SGLT2i is associated with reduced mortality from dementia, in contrast to insulin and sulfonylurea derivatives.SGLT2 inihibitors prevent cognitive impairment more potently than dipeptidylpeptidase-4 inhibitors. Taking empagliflozin for one month, is associated with improved cognitive function and increased scores on the Montreal Cognitive Assessment scale.

References

.Wróbel M, Rokicka D, Strojek K. Flozins - in the light of the latest recommendations. Endokrynol Pol. 2021;72(6):589-591. doi: 10.5603/EP.a2021.0098. PMID: 34970990.

.Kowalska, K.; Walczak, J.; Femlak, J.; Młynarska, E.; Franczyk, B.; Rysz, J. Empagliflozin—A New Chance for Patients with Chronic Heart Failure. Pharmaceuticals 2022, 15, 47. https://doi.org/10.3390/ph15010047

.Sim AY, Barua S, Kim JY, Lee YH, Lee JE. Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus. Front Neurosci. 2021 Aug 11;15:708547. doi: 10.3389/fnins.2021.708547. PMID: 34489627; PMCID: PMC8417940.

.Siao WZ, Lin TK, Huang JY, Tsai CF, Jong GP. The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: A nationwide population-based longitudinal cohort study. Diab Vasc Dis Res. 2022 May-Jun;19(3):14791641221098168. doi: 10.1177/14791641221098168. PMID: 35549730; PMCID: PMC9109279.

.Wu CY, Iskander C, Wang C, Xiong LY, Shah BR, Edwards JD, Kapral MK, Herrmann N, Lanctôt KL, Masellis M, Swartz RH, Cogo-Moreira H, MacIntosh BJ, Rabin JS, Black SE, Saskin R, Swardfager W. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study. Diabetes Care. 2023 Feb 1;46(2):297-304. doi: 10.2337/dc22-1705. PMID: 36508692.

.Jasleen B, Vishal GK, Sameera M, Fahad M, Brendan O, Deion S, Pemminati S. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk. Cureus. 2023 Jan 18;15(1):e33939. doi: 10.7759/cureus.33939. PMID: 36819350; PMCID: PMC9937770.

.Pawlos, A.; Broncel, M.; Woźniak, E.; Gorzelak-Pabiś, P. Neuroprotective Effect of SGLT2 Inhibitors. Molecules 2021, 26, 7213. https://doi.org/10.3390/molecules26237213

.Strona internetowa https://en.wikipedia.org/wiki/SGLT2_inhibitor dostęp 6.03.2023

.Strona interenetowa https://podyplomie.pl/kardiologia/28177,nowoczesne-leczenie-cukrzycy-typu-2-inhibitory-sglt2-dapagliflozyna?page=3 dostęp 7.03.2023

.Jardiance (empagliflozin) package insert. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield 2016

.Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, Ma M, Nakagawa T, Kusaka H, Kim-Mitsuyama S. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014 Oct 26;13:148. doi: 10.1186/s12933-014-0148-1. PMID: 25344694; PMCID: PMC4219031.

.Zhen YF, Zhang J, Liu XY, Fang H, Tian LB, Zhou DH, Kosten TR, Zhang XY. Low BDNF is associated with cognitive deficits in patients with type 2 diabetes. Psychopharmacology (Berl). 2013 May;227(1):93-100. doi: 10.1007/s00213-012-2942-3. Epub 2012 Dec 22. PMID: 23263460.

.Nakhal MM, Aburuz S, Sadek B, Akour A. Repurposing SGLT2 Inhibitors for Neurological Disorders: A Focus on the Autism Spectrum Disorder. Molecules. 2022 Oct 23;27(21):7174. doi: 10.3390/molecules27217174. PMID: 36364000; PMCID: PMC9653623.

.Iannantuoni, F.; M. de Marañon, A.; Diaz-Morales, N.; Falcon, R.; Bañuls, C.; Abad-Jimenez, Z.; Victor, V.M.; Hernandez-Mijares, A.; Rovira-Llopis, S. The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes. J. Clin. Med. 2019, 8, 1814. https://doi.org/10.3390/jcm8111814

Bos D, Vernooij MW, de Bruijn RF, Koudstaal PJ, Hofman A, Franco OH, van der Lugt A, Ikram MA. Atherosclerotic calcification is related to a higher risk of dementia and cognitive decline. Alzheimers Dement. 2015 Jun;11(6):639-47.e1. doi: 10.1016/j.jalz.2014.05.1758. Epub 2014 Aug 20. PMID: 25150731.

.Nguyen, T.T.; Ta, Q.T.H.; Nguyen, T.K.O.; Nguyen, T.T.D.; Van Giau, V. Type 3 Diabetes and Its Role Implications in Alzheimer’s Disease. Int. J. Mol. Sci. 2020, 21, 3165. www.doi.org/10.3390/ijms21093165

.Michailidis M, Moraitou D, Tata DA, Kalinderi K, Papamitsou T, Papaliagkas V. Alzheimer's Disease as Type 3 Diabetes: Common Pathophysiological Mechanisms between Alzheimer's Disease and Type 2 Diabetes. Int J Mol Sci. 2022 Feb 28;23(5):2687. doi: 10.3390/ijms23052687. PMID: 35269827; PMCID: PMC8910482.

.Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35. doi: 10.1038/nrm3025. Epub 2010 Dec 15. PMID: 21157483; PMCID: PMC3390257.

.Mao, Z.; Zhang, W. Role of mTOR in Glucose and Lipid Metabolism. Int. J. Mol. Sci. 2018, 19, 2043. https://doi.org/10.3390/ijms19072043

.Burillo, J.; Marqués, P.; Jiménez, B.; González-Blanco, C.; Benito, M.; Guillén, C. Insulin Resistance and Diabetes Mellitus in Alzheimer’s Disease. Cells 2021, 10, 1236. https://doi.org/10.3390/cells10051236

.Winslow BT, Onysko MK, Stob CM, Hazlewood KA. Treatment of Alzheimer disease. Am Fam Physician. 2011 Jun 15;83(12):1403-12. Erratum in: Am Fam Physician. 2014 Aug 15;90(4):209. PMID: 21671540.

.Reich N, Hölscher C. The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review. Front Neurosci. 2022 Sep 1;16:970925. doi: 10.3389/fnins.2022.970925. PMID: 36117625; PMCID: PMC9475012.

.Cummings JL, Tong G, Ballard C. Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options. J Alzheimers Dis. 2019;67(3):779-794. doi: 10.3233/JAD-180766. PMID: 30689575; PMCID: PMC6398562.

.Bendlin BB. Antidiabetic therapies and Alzheimer disease. Dialogues Clin Neurosci. 2019 Mar;21(1):83-91. doi: 10.31887/DCNS.2019.21.1/bblendin. PMID: 31607783; PMCID: PMC6780353.

.Lin, K.-J.; Wang, T.-J.; Chen, S.-D.; Lin, K.-L.; Liou, C.-W.; Lan, M.-Y.; Chuang, Y.-C.; Chuang, J.-H.; Wang, P.-W.; Lee, J.-J.; Wang, F.-S.; Lin, H.-Y.; Lin, T.-K. Two Birds One Stone: The Neuroprotective Effect of Antidiabetic Agents on Parkinson Disease—Focus on Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors. Antioxidants 2021, 10, 1935. https://doi.org/10.3390/antiox10121935

.Atiya A, Das Gupta D, Alsayari A, et al. Linagliptin and Empagliflozin Inhibit Microtubule Affinity Regulatory Kinase 4: Repurposing Anti-Diabetic Drugs in Neurodegenerative Disorders Using In Silico and In Vitro Approaches. ACS Omega. 2023 Feb;8(7):6423-6430. DOI: 10.1021/acsomega.2c06634. PMID: 36844587; PMCID: PMC9948186

.Strona internetowa https://www.alzheimers.gov/clinical-trials/dapagliflozin-alzheimers-disease dostęp (5.04.23)

.Roheger M, Kalbe E, Liepelt-Scarfone I. Progression of Cognitive Decline in Parkinson's Disease. J Parkinsons Dis. 2018;8(2):183-193. doi: 10.3233/JPD-181306. PMID: 29914040; PMCID: PMC6004891

.Ahmed S, El-Sayed MM, Kandeil MA, Khalaf MM. Empagliflozin attenuates neurodegeneration through antioxidant, anti-inflammatory, and modulation of α-synuclein and Parkin levels in rotenone-induced Parkinson's disease in rats. Saudi Pharm J. 2022 Jun;30(6):863-873. doi: 10.1016/j.jsps.2022.03.005. Epub 2022 Mar 16. PMID: 35812142; PMCID: PMC9257853.

.Nakhal, M.M.; Aburuz, S.; Sadek, B.; Akour, A. Repurposing SGLT2 Inhibitors for Neurological Disorders: A Focus on the Autism Spectrum Disorder. Molecules 2022, 27, 7174. https://doi.org/10.3390/molecules27217174

.Arab HH, Safar MM, Shahin NN. Targeting ROS-Dependent AKT/GSK-3β/NF-κB and DJ-1/Nrf2 Pathways by Dapagliflozin Attenuates Neuronal Injury and Motor Dysfunction in Rotenone-Induced Parkinson's Disease Rat Model. ACS Chem Neurosci. 2021 Feb 17;12(4):689-703. doi: 10.1021/acschemneuro.0c00722. Epub 2021 Feb 5. PMID: 33543924.

.Motawi TK, Al-Kady RH, Abdelraouf SM, Senousy MA. Empagliflozin alleviates endoplasmic reticulum stress and augments autophagy in rotenone-induced Parkinson's disease in rats: Targeting the GRP78/PERK/eIF2α/CHOP pathway and miR-211-5p. Chem Biol Interact. 2022 Aug 1;362:110002. doi: 10.1016/j.cbi.2022.110002. Epub 2022 May 30. PMID: 35654124.

.Ahmed S, El-Sayed MM, Kandeil MA, Khalaf MM. Empagliflozin attenuates neurodegeneration through antioxidant, anti-inflammatory, and modulation of α-synuclein and Parkin levels in rotenone-induced Parkinson's disease in rats. Saudi Pharm J. 2022 Jun;30(6):863-873. doi: 10.1016/j.jsps.2022.03.005. Epub 2022 Mar 16. PMID: 35812142; PMCID: PMC9257853.

.Sharma T, Kaur D, Grewal AK, Singh TG. Therapies modulating insulin resistance in Parkinson's disease: A cross talk. Neurosci Lett. 2021 Apr 1;749:135754. doi: 10.1016/j.neulet.2021.135754. Epub 2021 Feb 18. PMID: 33610666.

.Strona internetowa https://www.who.int/news-room/fact-sheets/detail/dementia dostęp 08.04.23

.Secnik J, Xu H, Schwertner E, Hammar N, Alvarsson M, Winblad B, Eriksdotter M, Garcia-Ptacek S, Religa D. Dementia Diagnosis Is Associated with Changes in Antidiabetic Drug Prescription: An Open-Cohort Study of ∼130,000 Swedish Subjects over 14 Years. J Alzheimers Dis. 2020;76(4):1581-1594. doi: 10.3233/JAD-200618. PMID: 32741836; PMCID: PMC7504989.

.Secnik J, Cermakova P, Fereshtehnejad SM, Dannberg P, Johnell K, Fastbom J, Winblad B, Eriksdotter M, Religa D. Diabetes in a Large Dementia Cohort: Clinical Characteristics and Treatment From the Swedish Dementia Registry. Diabetes Care. 2017 Sep;40(9):1159-1166. doi: 10.2337/dc16-2516. Epub 2017 Jun 27. PMID: 28655740; PMCID: PMC5566285.

.Secnik J, Xu H, Schwertner E, Hammar N, Alvarsson M, Winblad B, Eriksdotter M, Garcia-Ptacek S, Religa D. Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia. J Alzheimers Dis. 2022;86(1):245-257. doi: 10.3233/JAD-215337. PMID: 35034902; PMCID: PMC9028644.

.Sa-Nguanmoo P, Tanajak P, Kerdphoo S, Jaiwongkam T, Pratchayasakul W, Chattipakorn N, Chattipakorn SC. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats. Toxicol Appl Pharmacol. 2017 Oct 15;333:43-50. doi: 10.1016/j.taap.2017.08.005. Epub 2017 Aug 12. PMID: 28807765.

.Che-Yuan Wu, Carina Iskander, Christa Wang, Lisa Y. Xiong, Baiju R. Shah, Jodi D. Edwards, Moira K. Kapral, Nathan Herrmann, Krista L. Lanctôt, Mario Masellis, Richard H. Swartz, Hugo Cogo- Moreira, Bradley J. MacIntosh, Jennifer S. Rabin, Sandra E. Black, Refik Saskin, Walter Swardfager; Związek inhibitorów kotransportera sodowo-glukozowego 2 z czasem do demencji: populacyjne badanie kohortowe. Opieka nad cukrzycą 1 lutego 2023; 46 (2): 297–304. https://doi.org/10.2337/dc22-1705

.Mone P, Lombardi A, Gambardella J, Pansini A, Macina G, Morgante M, Frullone S, Santulli G. Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction. Diabetes Care. 2022 May 1;45(5):1247-1251. doi: 10.2337/dc21-2434. PMID: 35287171; PMCID: PMC9174954.

.Yabe D, Shiki K, Suzaki K, Meinicke T, Kotobuki Y, Nishida K, Clark D, Yasui A, Seino Y. Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes. BMJ Open. 2021 Apr 7;11(4):e045844. doi: 10.1136/bmjopen-2020-045844. PMID: 33827843; PMCID: PMC8031078.

Downloads

Published

2023-05-02

How to Cite

1.
LATO, Marta, IBERSZER, Konrad, LITWINIUK, Maria, ZANIUK, Marcin, HURKAŁA, Kamil, ANTONIK, Dominika, DENYS, Barbara, GÓRA, Karolina, ZDZIENNICKI, Wojciech and ZIMNICKI, Patryk. The use of SGLT2 inhibitors in the treatment of cognitive disorders. Journal of Education, Health and Sport. Online. 2 May 2023. Vol. 25, no. 1, pp. 27-39. [Accessed 25 December 2024]. DOI 10.12775/JEHS.2023.25.01.003.

Issue

Vol. 25 No. 1 (2023)

Section

Articles

License

Copyright (c) 2023 Marta Lato, Konrad Iberszer, Maria Litwiniuk, Marcin Zaniuk, Kamil Hurkała, Dominika Antonik, Barbara Denys, Karolina Góra, Patryk Zimnicki, Wojciech Zdziennicki

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0

Stats

Number of views and downloads: 904
Number of citations: 0